Date: 2013-09-18
Type of information: Collaboration agreement
Compound: Xilonix™
Company: Xbiotech (USA - TX) US Oncology Research
Therapeutic area: Cancer - Oncology
Type agreement: collaboration clinical research
Action mechanism: monoclonal antibody. Xilonix™ is a first-in-class True Human™ antibody that blocks inflammation involved in tumor growth and metastasis. Sterile inflammation caused by malignant tumors is known to stimulate angiogenesis and tissue matrix remodeling, key steps in ongoing tumor growth and spread. Patients receiving Xilonix in an earlier study have shown improved overall survival and recovery of lean body tissue.
Disease: colorectal cancer
Details: * On September 18, 2013, XBiotech, a privately held biotechnology company, announced its collaboration with US Oncology Research to conduct a pivotal Phase III Trial for colorectal cancer. Through the collaboration, US Oncology Research will leverage its national network of affiliated oncology centers to treat patients with XBiotech's new anti-cancer therapy and report clinical outcomes. Patients enrolled in the trial will receive at least the current standard of care. With nearly 225 affiliated treatment research locations, US Oncology Research is one of the largest organizations in America focused on bringing physicians, clinics and patients together for innovative cancer care. Based on earlier clinical studies, it's anticipated that XBiotech's new therapy for colorectal cancer could show an improved survival rate for colorectal cancer patients, while at the same time facilitate recovery from the effects of cachexia, which is present in most patients with advanced colorectal cancer. US Oncology Research will join XBiotech's pivotal Phase III study, which has been granted FDA Fast Track status. XBiotech plans to have 100 sites in the United States, with results intended to provide the basis for marketing approval.
Financial terms:
Latest news:
